DEXA-BEAM Salvage Chemotherapy and High-Dose Chemotherapy Followed by Autologous Bone Marrow Transplantation in Hodgkin’s Disease

  • N. Schmitz
  • M. Pfreundschuh
  • V. Diehl
  • The German Hodgkin Study Group
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)

Abstract

Patients with advanced stage Hodgkin’s disease (HD) who fail first-line therapy or relapse within the first 12 months after having achieved a complete remission with combination chemotherapy (and radiotherapy) generally have a poor prognosis [1,2]. In an effort to improve the results of salvage therapy in such patients the German Hodgkin Study Group has followed various treatment strategies most recently including a new chemotherapy regimen consisting of dexamethasone, BCNU, cytosine-arabinoside, and melphalan (DEXA-BEAM). Other poor-risk patients have received high-dose chemotherapy (HDCT) followed by autologous bone marrow transplantation (ABMT). We report early results of both conventional and high-dose chemotherapy and demonstrate that DEXA-BEAM chemotherapy followed by HDCT/ABMT has substantial antitumor activity but lacks severe toxicity in most instances.

Keywords

Lymphoma Dexamethasone Doxorubicin Melphalan Cyclophosphamide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, DeVita DT Jr (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10: 210–218PubMedGoogle Scholar
  2. 2.
    Hoppe RT (1991) Development of effective salvage treatment programs for Hodgkin’s disease: An ongoing clinical challenge. Blood 77: 2093–2095PubMedGoogle Scholar
  3. 3.
    Hiddemann W, Schmitz N, Pfreundschuh M, Pflüger KH, Ollech-Chwoyka J, Tirier C, Maschmeyer G, Kirchner H, Wagner T, Koch P, Dahmen E, Fiedler W, Trümper L, Diehl V (1990) Treatment of refractory Hodgkin’s disease with high-dose cytosine arabinoside and mitoxantrone in combination. Cancer 66: 838–843PubMedCrossRefGoogle Scholar
  4. 4.
    Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, Bariogie B (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71: 117–122PubMedGoogle Scholar
  5. 5.
    Pfreundschuh MG, Schoppe WD, Fuchs R, Pflüger KH, Loeffier M, Diehl V (1987) Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin’s lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and darcabazine (ABVD): A multicenter trial of the German Hodgkin’s Study Group. Cancer Treat Rep 71: 1203–1207PubMedGoogle Scholar
  6. 6.
    Cervantes F, Reverter JC, Montserrat E, Rozman C (1986) Treatment of advanced resistant Hodgkin’s disease with lomustine, etoposide and prednimustine. Cancer Treat Rep 70: 665–667PubMedGoogle Scholar
  7. 7.
    Tseng A Jr, Jacobs C, Coleman CN, Horning SJ, Lewis BJ, Rosenberg SA (1987) Third-line chemotherapy for resistant Hodgkin’s disease with lomustine, etoposide and methotrexate. Cancer Treat Rep 71: 475–478PubMedGoogle Scholar
  8. 8.
    Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, Vaughan WP, Kessinger A, Horwitz LJ, Hagemeister FB, McLaughlin P, Cabanillas F, Spitzer G (1989) Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 7: 179–185PubMedGoogle Scholar
  9. 9.
    Reece DE, Barnett MJ, Connors JM, Fairey RN, Greer JP, Herzig GP, Herzig RH, Klingemann HG, O’Reilly SE, Shepherd JD, Spinelli JJ, Voss NJ, Wolff SN, Phillips GL (1991) Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 9: 1871–1879PubMedGoogle Scholar
  10. 10.
    Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G, Meloni G, Cimino G, Mangoni L, Coser P, Cetto GL, Cimino R, Alessandrino EP, Brusamolino E, Santini G, Tura S, Mandelli F, Rizzoli V, Bernasconi C, Marmont AM (1988) High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin’s disease patients: An Italian Study Group report. J Clin Oncol 6: 1411–1416PubMedGoogle Scholar
  11. 11.
    Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE, Eder JP (1990) Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin’s disease and non-Hodgkin’s lymphoma: A dose-finding study. J Clin Oncol 8: 648–656PubMedGoogle Scholar
  12. 12.
    Surbone A, Armitage JO, Gale RP (1991) Autotransplantation in lymphoma: Better therapy or healthier patients? Ann Intern Med 114: 1059–1060PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • N. Schmitz
    • 1
  • M. Pfreundschuh
    • 1
  • V. Diehl
    • 1
  • The German Hodgkin Study Group
  1. 1.II. Medizinische Klinik und Poliklinikder Christian-Albrechts-Universität KielKiel 1Germany

Personalised recommendations